title: Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma.
abstract: OBJECTIVE
  There is scant information on the morbidity associated with subclinical Cushing's syndrome in patients with a clinically inapparent adrenal adenoma. In the present study, we have determined the prevalence of alterations of the hypothalamic-pituitary-adrenal axis in such patients and examined whether any correlation between endocrine data and the clinical phenotype exists.
  
  
  METHODS
  A multi-institutional retrospective study was carried out on 210 patients (135 women and 75 men aged 19-81 years) with an adrenal adenoma detected serendipitously between 1996 and 2000 in four referral centers in Italy.
  
  
  RESULTS
  Hypertension was observed in 53.8%, obesity in 21.4% and hyperglycemia in 22.4% of patients. The 47 patients with midnight serum cortisol >5.4 microg/dl, a value corresponding to the 97th centile of 100 controls, were older and displayed greater fasting glucose (120.4+/-52.2 mg/dl vs 105.1+/-39.2 mg/dl, P = 0.04) and systolic blood pressure (148.3+/-14.6 mmHg vs 136.4+/-16.2 mmHg, P = 0.0009) than the 113 patients with normal cortisol levels. The difference in systolic blood pressure remained statistically significant (P = 0.009) when age was used as a covariate. The percentage of hypertensive patients undergoing treatment was not different between the two groups (90.5 and 97.1%) but the percentage of patients with controlled hypertension was significantly lower among the hypercortisolemic patients (12.5 vs 32.4%, P = 0.04). Glycated haemoglobin (HbA1c) levels were higher in the hypercortisolemic diabetic patients (8.9+/-1.1% vs 7.1+/-1.3%, P = 0.005).
  
  
  CONCLUSIONS
  Elevated midnight cortisol concentration is a reliable test to select a subgroup of patients with a clinically inapparent adrenal adenoma with an adverse cardiovascular risk profile.
authors.affiliation: Dipartimento di Scienze Cliniche e Biologiche, Medicina Interna I, Università di Torino, Turin, Orbassano, Italy. terzolo@usa.net
authors.forename: Massimo
authors.initials: M
authors.lastname: Terzolo
authors.forename: Silvia
authors.initials: S
authors.lastname: Bovio
authors.forename: Anna
authors.initials: A
authors.lastname: Pia
authors.forename: Pier Antonio
authors.initials: PA
authors.lastname: Conton
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Reimondo
authors.forename: Chiara
authors.initials: C
authors.lastname: Dall'Asta
authors.forename: Donatella
authors.initials: D
authors.lastname: Bemporad
authors.forename: Alberto
authors.initials: A
authors.lastname: Angeli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Opocher
authors.forename: Massimo
authors.initials: M
authors.lastname: Mannelli
authors.forename: Bruno
authors.initials: B
authors.lastname: Ambrosi
authors.forename: Franco
authors.initials: F
authors.lastname: Mantero
mesh_terms: D000236:Adenoma / Q000097:blood* / Q000453:epidemiology; D000310:Adrenal Gland Neoplasms / Q000097:blood* / Q000453:epidemiology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002940:Circadian Rhythm; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D006973:Hypertension / Q000097:blood* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D019314:Dehydroepiandrosterone Sulfate; D006854:Hydrocortisone